Cargando…

Gauging ASCVD Risk, Does Race Matter?

[Figure: see text]

Detalles Bibliográficos
Autores principales:	Zuo, Ming-Liang, Siu, Chung-Wah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627924/ https://www.ncbi.nlm.nih.gov/pubmed/36340247 http://dx.doi.org/10.1016/j.jacasi.2021.12.006

Ejemplares similares

Association of hyperuricemia combined with sarcopenia on ASCVD risk
por: Nie, Guqiao, et al.
Publicado: (2023)

Highlights in ASCVD Primary Prevention for 2021
por: Polonsky, Tamar S., et al.
Publicado: (2022)

The Potential Role of Biomarkers Associated with ASCVD Risk: Risk-Enhancing Biomarkers
por: Choi, Seonghoon
Publicado: (2019)

Combination of Endoglin and ASCVD Risk Assessment Improves Carotid Subclinical Atherosclerosis Recognition
por: Li, Qiaowei, et al.
Publicado: (2020)

Comparison of Framingham Cardiovascular Risk Criteria and ASCVD Score in Iranian Obese Patients
por: Hasani-Ranjbar, Shirin, et al.
Publicado: (2023)

Marital Status and Risk of Dementia: Does Race Matter?
por: Zhang, Zhenmei, et al.
Publicado: (2020)

Health Literacy is Essential to ASCVD Prevention in Youth
por: Mann, Harnoor K., et al.
Publicado: (2023)

IMPACT OF THE COVID-19 PANDEMIC ON THE MANAGEMENT OF RISK FACTORS IN PATIENTS WITH ASCVD
por: Karalis, Dean, et al.
Publicado: (2023)

Identifying Opportunities for Impact of Community-Based Pharmacist-Led Biometric Health Screenings on ASCVD Risk
por: Newell, Bradley J., et al.
Publicado: (2023)

A tool to help patients visualize ASCVD risk and the potential impact of risk-lowering interventions
por: Mendez, Keegan, et al.
Publicado: (2022)

RELATION OF 10-YEAR ASCVD RISK SCORE WITH SEVERE COVID-19 OUTCOMES
por: Arif, Yousif, et al.
Publicado: (2022)

Newer and Emerging LDL-C Lowering Agents and Implications for ASCVD Residual Risk
por: Rikhi, Rishi, et al.
Publicado: (2022)

Metabolomics profile and 10-year atherosclerotic cardiovascular disease (ASCVD) risk score
por: Dehghanbanadaki, Hojat, et al.
Publicado: (2023)

Analisi di costo-utilità di evolocumab in pazienti con ASCVD in Italia
por: Marcellusi, Andrea, et al.
Publicado: (2021)

10-year ASCVD risk is positively correlated with depressive symptoms in a large general population
por: Sun, Guo-Zhe, et al.
Publicado: (2019)

Cost effectiveness of interventions to improve adherence to statin therapy in ASCVD patients in the United States
por: Armstrong, Shannon O, et al.
Publicado: (2019)

COVID-19 associated risks of myocardial infarction in persons with familial hypercholesterolemia with or without ASCVD
por: Myers, Kelly D., et al.
Publicado: (2021)

External validation of the ACC/AHA ASCVD risk score in a Colombian population cohort
por: Rodríguez-Ariza, Carlos Daniel, et al.
Publicado: (2023)

Effects of weight change on apolipoprotein B-containing emerging atherosclerotic cardiovascular disease (ASCVD) risk factors
por: Dansinger, Michael L., et al.
Publicado: (2019)

Apolipoprotein E polymorphisms contribute to statin response in Chinese ASCVD patients with dyslipidemia
por: Zhang, Lei, et al.
Publicado: (2019)

Expanding statin use for prevention of ASCVD in Indians: Reasoned and simplified proposals
por: Enas, Enas A., et al.
Publicado: (2020)

Chinese ASCVD risk equations rather than pooled cohort equations are better to identify macro- and microcirculation abnormalities
por: Li, Qiaowei, et al.
Publicado: (2020)

Ten-year risk assessment for cardiovascular diseases using ASCVD risk estimator plus: outcomes from hypertension and diabetes patients
por: Osoro, Ian, et al.
Publicado: (2023)

DOES RACE MATTER IN HEALTH MESSAGING? IMPACT OF RACE CONCORDANCE ON PALLIATIVE CARE KNOWLEDGE SCORE
por: Hoe, Deborah, et al.
Publicado: (2022)

Uterine clear cell carcinoma risk in White versus non-White US subpopulations: does race matter?
por: Chow, Stephanie, et al.
Publicado: (2020)

Relationship of Noninvasive Assessment of Arterial Stiffness with 10-Year Atherosclerotic Cardiovascular Disease (ASCVD) Risk in a General Middle-Age and Elderly Population
por: Wang, Hao, et al.
Publicado: (2021)

Adherence to Cardiovascular Disease Medications: Does Patient-Provider Race/Ethnicity and Language Concordance Matter?
por: Traylor, Ana H., et al.
Publicado: (2010)

Parâmetros Ecocardiográficos Simples podem Substituir o Cálculo do Modelo Probabilístico ASCVD?
por: Silva, Tonnison de Oliveira, et al.
Publicado: (2022)

L-Arginine, Nitric Oxide, and Endothelial Dysfunction Underlying Atherosclerotic Cardiovascular Disease (ASCVD)
por: Shimabukuro, Michio
Publicado: (2023)

MAFLD and ASCVD: Plasma Heparin Cofactor II Activity as an Anti-liver Fibrosis Biomarker
por: Shimabukuro, Michio
Publicado: (2023)

Letter to the Editor on “Atrial fibrillation prevalence and risk profile from novel community-based screening in Thailand: A prospective multi-centre study”
por: Zuo, Ming-Liang, et al.
Publicado: (2021)

Utility of coronary artery calcium in refining 10-year ASCVD risk prediction using a Thai CV risk score
por: Tiansuwan, Noppanat, et al.
Publicado: (2023)

Sex-specific performance of the ASCVD pooled cohort equation risk calculator as a correlate of coronary artery calcium in Kampala, Uganda
por: Kentoffio, Katherine, et al.
Publicado: (2022)

MBOAT7 rs641738 (C>T) is associated with NAFLD progression in men and decreased ASCVD risk in elder Chinese population
por: Xu, Xiaoyi, et al.
Publicado: (2023)

Gauge fields in condensed matter
por: Kleinert, Hagen
Publicado: (1989)

Healthcare Resource Utilization, Cardiovascular Event Rate and Use of Lipid-Lowering Therapies in Secondary Prevention of ASCVD in Hospitalized Patients in Italy
por: Sciattella, Paolo, et al.
Publicado: (2021)

Estimated ASCVD risk according to statin use in US adults with borderline triglycerides: Results from National Health and Nutrition Examination Survey (NHANES) 2007–2014
por: Fan, Wenjun, et al.
Publicado: (2020)

Long-Term Outcomes Associated with NAFLD, ASCVD, and All-Cause Mortality of Patients with Metabolic Syndrome
por: Jitrukthai, Suchanart, et al.
Publicado: (2022)

The Effects of Intensive Blood Pressure Control on Cardiovascular Outcomes Based on 10-Year ASCVD Risk Score: An Analysis of a Clinical Trial
por: Alborzi, Alireza, et al.
Publicado: (2021)

Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From DA VINCI
por: Vallejo-Vaz, Antonio J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mh7u83jkn8bvdv72lqpe5p6b61